The story
The next indication chosen on ecosystem readiness, with a basis the team could defend.
A pipeline decision is also a disease decision. We landscaped a shortlist of rare disease areas side by side: KOL mapping, diagnostic pathways, treatment context, trial precedent and endpoint availability. That showed which indication gave the asset the strongest realistic path to patients. The prioritisation could then be defended, not just asserted.
A biopharma company held a promising asset and more than one rare disease area where it could plausibly be developed. Each candidate had been assessed in isolation, on different bases, by different people. There was no common frame for comparison, and a real risk the decision would default to whichever disease area the organisation knew best rather than where the asset fit best.
The difficulty is structural. Rare disease landscapes differ enormously, so a like-for-like comparison needs a consistent framework, not disease-specific intuition. Unmet need is easy to state and hard to verify without mapping the actual diagnostic and treatment pathway. A disease can look attractive on prevalence alone while its ecosystem is poorly positioned to adopt a new treatment quickly, or lacks a trial endpoint that regulators and clinicians accept as meaningful.
One framework, every candidate
We landscaped each candidate disease area on the same terms: the diagnostic pathway, the stakeholder field, the current treatment context, and where patients are genuinely underserved. Alongside that we reviewed the trial history in each area, looking at which endpoints have precedent, which are regulator-accepted, and where no clear path to a viable endpoint yet exists. Finally we assessed how ready each ecosystem was to adopt a new asset at all.
The disease-by-disease pictures then came together in a single structured comparison. For the first time, the pipeline decision had a common basis.
Defensible, not just familiar
The company prioritised the indication where unmet need, ecosystem readiness and trial feasibility aligned. The choice now rests on mapped evidence rather than internal familiarity, with a structured rationale the team can defend internally and to its board.
"For the first time we could see the candidate diseases in the same frame, on the same terms. That made the choice defensible, rather than just familiar."